| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/14/2008 | US20080038349 Peptide-Pna Chimera Targeting Inducible Nitric Oxide Synthetase |
| 02/14/2008 | US20080038327 comprising S-sulfonated keratin associated with a water soluble polymer through hydrogen bonding and further comprising a protein cross-linking agent |
| 02/14/2008 | US20080038320 Compositions and methods for enhancing vasodilation |
| 02/14/2008 | US20080038317 Therapeutic Lacrimal Canalicular Inserts And Related Methods |
| 02/14/2008 | US20080038312 Insertable or implantable medical devices suitable for gene therapy regimens |
| 02/14/2008 | US20080038310 Coating comprising an elastin-based copolymer |
| 02/14/2008 | US20080038309 Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human Box-A of HMGB1 to prevent and/or antagonize pathologies induced by HMGB1 |
| 02/14/2008 | US20080038299 Skincare Compositions Comprising Salicylic Acid |
| 02/14/2008 | US20080038292 comprises alkali metal salt, alkaline earth metal salt, and citrate/phosphate buffer; improved stability |
| 02/14/2008 | US20080038285 Method for Identifying and Quantifying of Tumour-Associated |
| 02/14/2008 | US20080038284 Human Immunodeficiency Virus Vaccine |
| 02/14/2008 | US20080038281 Model membrane systems |
| 02/14/2008 | US20080038278 GPAT3 encodes a mammalian, microsomal acyl-coa:glycerol 3- phosphate acyltransferase |
| 02/14/2008 | US20080038277 Dna Pkinase Inhibitors For Treating Cancer And Diabetes |
| 02/14/2008 | US20080038274 Inhibition of secretion from non-neuronal cells |
| 02/14/2008 | US20080038273 Preventing CD28 binding to B7 by monovalent fragments antibody called CD28.3 of which exhibit sufficient affinity for the antigen so that they can be used, in vitro or in vivo, to block the CD28 receptor without activation of this receptor; autoimmune diseases; transplant rejection |
| 02/14/2008 | US20080038267 Treatment Of Cancer |
| 02/14/2008 | US20080038266 Antibody or antigen binding fragment that binds acetyl-coA-acetyltransferase of Clostridium difficile |
| 02/14/2008 | US20080038264 Compositions and methods for the treatment of immune related diseases |
| 02/14/2008 | US20080038262 Using immunoglobulin specific to shiga-like toxin as therapeutic tool in treatment and prevention of enterohemorrhagic escherichia infection |
| 02/14/2008 | US20080038261 Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| 02/14/2008 | US20080038258 Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making |
| 02/14/2008 | US20080038255 Splice Variant of Unc5h2 |
| 02/14/2008 | US20080038251 MN/CA IX and MAPK inhibition |
| 02/14/2008 | US20080038249 Treatment Of Neurodegenerative Diseases By The Use Of Laptm4a |
| 02/14/2008 | US20080038248 Proteins Ligands For Nkg2d And Ul16 Receptors And Uses Thereof |
| 02/14/2008 | US20080038247 Diagnostics and Therapeutics for Diseases Associated With G-Protein-Coupled Receptor Gpr39 (Gpr39) |
| 02/14/2008 | US20080038246 Crystallized Oxalate Decarboxylase And Methods Of Use |
| 02/14/2008 | US20080038245 Methods of modulating angiogenesis |
| 02/14/2008 | US20080038244 Materials and Methods Relating to Cell Cycle Control |
| 02/14/2008 | US20080038243 Wound healing compositions and methods using tropoelastin and lysyl oxidase |
| 02/14/2008 | US20080038242 sodium-dependent nucleoside transporter 2 inhibitors; for diseases associated with abnormal plasma uric acid levels such as gout, hyperuricemia, urinary lithiasis, hyperuriciemic nephropathy, and acute uric acid nephropathy |
| 02/14/2008 | US20080038240 Using bacillus coagulans inoculation to increase carbohydrate absorption in mammals and reduce symptoms of gastrointestinal distress |
| 02/14/2008 | US20080038235 Methods for regulating T cell subsets by modulating transcription factor activity |
| 02/14/2008 | US20080038234 Bone Marrow-Related Cells Associated With Tissue Maintenance And/Or Repair |
| 02/14/2008 | US20080038232 Production of high mannose proteins in plant culture |
| 02/14/2008 | US20080038225 Triazolyl acyclic hepatitis c serine protease inhibitors |
| 02/14/2008 | US20080038224 Modified interferon-beta (IFN-beta) polypeptides |
| 02/14/2008 | US20080038223 WSX-1/P28 as a target for anti-inflammatory responses |
| 02/14/2008 | US20080038222 Composition Comprising Colony Stimulating Factor for Treatment of a Localised Bacterial Infection and Bacterial Related Disease |
| 02/14/2008 | US20080038208 Pharmaceutical/cosmetic compositions comprising the lysine-d-proline-valine tripeptide |
| 02/14/2008 | US20080038205 Novel dermatophagoides proteins |
| 02/14/2008 | US20080038203 Compositions and Methods for Topical Diagnostic and Therapeutic Transport |
| 02/14/2008 | US20080038200 Model for neurodegenerative diseases involving amyloid accumulation |
| 02/14/2008 | US20080038199 Methods Related to the Treatment of Neurodegenerative and Inflammatory Conditions |
| 02/14/2008 | US20080035141 Aerosolized therapy kit |
| 02/14/2008 | CA2694289A1 Polymyxin derivatives and uses thereof |
| 02/14/2008 | CA2679707A1 Detection of protease and protease activity using a single nanoscrescent sers probe |
| 02/14/2008 | CA2661446A1 Treatment of pulmonary disease conditions |
| 02/14/2008 | CA2660689A1 Spinal nerve repair promoting therapeutics containing des-acyl ghrelin or its derivatives as an active ingredient |
| 02/14/2008 | CA2660517A1 Spinal nerve repair promoting therapeutics containing ghrelin or its derivatives or substances that act on ghs-rla as an active ingredient |
| 02/14/2008 | CA2660356A1 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| 02/14/2008 | CA2660345A1 Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| 02/14/2008 | CA2660235A1 Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
| 02/14/2008 | CA2660183A1 Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer |
| 02/14/2008 | CA2659990A1 Polyethylene glycol erythropoietin conjugates |
| 02/14/2008 | CA2659809A1 Long half-life recombinant butyrylcholinesterase |
| 02/14/2008 | CA2659337A1 Combination therapy |
| 02/14/2008 | CA2659289A1 Compounds for improving learning and memory |
| 02/14/2008 | CA2656816A1 Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| 02/14/2008 | CA2653974A1 Detecting and treating dementia |
| 02/14/2008 | CA2642494A1 Novel phosphopeptides and uses thereof in preventing kidney stone formation |
| 02/13/2008 | EP1887082A2 TADG-15: An extracellular serine protease overexpressed in carcinomas |
| 02/13/2008 | EP1887016A1 Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| 02/13/2008 | EP1887015A2 Method for extracting and using new human defence agents and biologically active proteins for treating infections and other illnesses |
| 02/13/2008 | EP1887014A1 Human toll homologues |
| 02/13/2008 | EP1886692A1 Agent for improvement of insulin resistance |
| 02/13/2008 | EP1886691A2 A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug |
| 02/13/2008 | EP1886690A2 Pharmaceutical composition for the treatment of food intolerance |
| 02/13/2008 | EP1886677A1 Use of an inducing agent for the treatment of blood, viral and cellular disorders |
| 02/13/2008 | EP1886668A1 Controlled release compositions for interferon based on block polymers |
| 02/13/2008 | EP1885872A1 Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction |
| 02/13/2008 | EP1885851A1 Methods for diagnosing epigenetic, transgenerational effects of environmental toxicants on mammalian germ-lines and treating associated diseases |
| 02/13/2008 | EP1885754A2 T cell receptors which specifically bind to vygfvracl-hla-a24 |
| 02/13/2008 | EP1885752A2 Modified leukocyte ig-like receptor family members (lir's) with increased affinity for class i mhc and their uses in modulating t cell activation |
| 02/13/2008 | EP1885751A1 Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof |
| 02/13/2008 | EP1885750A1 Bone morphogenetic protein 4 and osteogenic devices and pharmaceutical products containing thereof |
| 02/13/2008 | EP1885749A1 Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof |
| 02/13/2008 | EP1885745A2 Use of h11 protein in in vitro diagnosis of streptococcus pyogenes infections |
| 02/13/2008 | EP1885744A2 Novel substrate for rpn 11 enzymatic activity |
| 02/13/2008 | EP1885743A1 BACKBONE CYCLIZED MELANOCORTIN STIMULATING HORMONE ( alpha S ) ANALOGS |
| 02/13/2008 | EP1885742A1 Compositions for targeting amine oxidases in vivo |
| 02/13/2008 | EP1885741A1 Lys-thr dipeptides and their use |
| 02/13/2008 | EP1885395A2 A method for improving the immunogenicity of plasmodium antigens |
| 02/13/2008 | EP1885392A2 Insulins combinations |
| 02/13/2008 | EP1885391A1 Use of glp-2 for the treatment of ischemia-reperfusion injury |
| 02/13/2008 | EP1885390A2 Use of peptides derived from the growth factor amp-18 for the treatment of mucositis |
| 02/13/2008 | EP1885389A1 Use of adnf polypeptides for treating peripheral neurotoxicity |
| 02/13/2008 | EP1885387A2 Thrombin purification |
| 02/13/2008 | EP1885386A2 Non-natural chemokine receptor ligands and methods of use thereof |
| 02/13/2008 | EP1885385A2 Phosphatidylinositol combination composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases |
| 02/13/2008 | EP1885384A1 Treating liver diseases |
| 02/13/2008 | EP1885365A2 Treatment of sepsis and inflammation with alpha2a adrenergic antagonists |
| 02/13/2008 | EP1885360A2 Inhibition of neuronal damage |
| 02/13/2008 | EP1885354A2 Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis |
| 02/13/2008 | EP1885335A1 Surface-modified microparticles and methods of forming and using the same |
| 02/13/2008 | EP1827482A4 Novel uses of egf |
| 02/13/2008 | EP1758923B1 Peptide substance restoring myocardium function |
| 02/13/2008 | EP1758922B1 Peptide substance restoring function of respiratory organs |
| 02/13/2008 | EP1740203A4 Polypeptide inducing the secretion of angiopoietin |